Biotech Values

[biomaven0]

Qnexa will have less than a 40% Rx share of the combined market for Qnexa and the off-label generic constituents

Not sure what the number will be as it depends on the REMS and on pricing/insurance coverage, but I would predict distinctly north of 50% - if I had to pick a number, I'd pick mid 60's.

Peter